Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 February 2024 | Story André Damons | Photo SUPPLIED
Prof Robert Bragg
Prof Robert Bragg is a researcher in the Department of Microbiology and Biochemistry at the University of the Free State (UFS) and believes hospital-acquired infections (HAIs) might already be “Disease X”.

During the World Governments Summit, the World Health Organisation (WHO) warned world leaders about the likelihood of a Disease X outbreak, saying it is “a matter of when, not if” a new pathogen and pandemic will strike. If there is an outbreak of this disease tomorrow, the world still would not be ready. 

During his speech earlier this month at the summit in Dubai, Tedros Adhanom Ghebreyesus, Director-General of the WHO, said COVID-19 was a Disease X – a new pathogen causing a new disease. He said: “There will be another Disease X, or a Disease Y or a Disease Z. And as things stand, the world remains unprepared for the next Disease X, and the next pandemic. If it struck tomorrow, we would face many of the same problems we faced with COVID-19.”

Though Disease X is a hypothetical placeholder representing yet-to-be-encountered pathogens, Prof Robert Bragg, researcher in the Department of Microbiology and Biochemistry at the University of the Free State (UFS), believes hospital-acquired infections (HAI) might already be “Disease X”. He says data shows that deaths from HAIs will become the leading cause of human deaths. This problem is rapidly growing as most of the pathogens which people contract while in hospital are now resistant to antibiotics, making them very difficult to treat.  

Prof Bragg, whose main research is in disease-control, first in the agricultural industry, and now human health, also previously warned about a disease that would make COVID-19, which killed more than seven million people to date globally, look like a dress rehearsal. His PhD student, Samantha Mc Carlie, investigating how bacteria become resistant to disinfectant and sanitiser products. This is a serious problem for the future, as disinfection could be our last line of defence.

Heading for a crisis in health care

“The world is rapidly heading for a crisis in health care regarding hospital-acquired infections. It is common knowledge that we are quickly running out of antibiotics (and antifungals) to treat bacterial and yeast infections. Without antibiotics and antifungals, the outcome of many of these bacterial and yeast hospital-acquired infections will be very severe. They will, unfortunately, in many cases, result in the death of the patient,” says Prof Bragg. 

According to him, the WHO suggests that 30% of patients in ICUs in developed countries and 70% in underdeveloped countries will contract a HAI. Of these, the mortality rate can be as high as 70%. 

“Most of these infections are caused by multiple drug resistance strains of bacteria such as Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species. Additional bacteria and yeast, which can also cause HAIs, such as Serratia species, are also becoming a concern due to their intrinsic higher levels of disinfectant resistance.”

Prof Bragg explains that in 2014, a high-profile review was first published, commissioned by the UK Prime Minister, entitled, “Antimicrobial Resistance: Tackling a crisis for the Health and Wealth of Nations” (the AMR Review). This review estimated that antimicrobial resistance (AMR) could cause 10 million deaths annually by 2050 (The Review on Antimicrobial Resistance 2016). This is the same number of deaths caused by cancer today, making AMR the leading cause of human mortality by 2050. When it was finalised, this report was highly criticised as an over-dramatisation, as when this prediction was made, the number of mortalities related to HAIs was around 700 000 – a very long way off 10 000 000. However, according to recent estimates, five years later, in 2019, 1.27 million deaths were directly attributed to drug-resistant infections globally, and this had reached 4.95 million deaths associated with bacterial AMR (including those directly attributable to AMR) by 2022 (Murray et al. 2022). 

The overuse of disinfectants during the COVID-19 pandemic, according to Prof Bragg and Mc Calie, has contributed to the crisis by fostering resistant strains and contaminating environments. Based on the current trajectory of mortalities, the 10 million mark will be reached way before 2050.

Need for a paradigm shift

The researchers say an urgent need to change the paradigm in medicine from “treatment” to “prevention” is necessary and that the old saying ‘prevention is better than cure’ has never been truer. 

According to Bragg: “The golden era of antibiotics is rapidly coming to an end. It is highly unlikely that we will discover new antibiotics, and even if we do, the likelihood that the bacteria will already have or will be able to develop resistance in a very short time is highly likely. 

“We need to think of what happed with quinolones, where we thought we had won the war with a groundbreaking new antimicrobial agent. The bacteria did not have millions of years of evolution to develop resistance to quinolone, yet in only three years, the first resistant bacteria were isolated. There is currently great excitement around AI-derived new antibiotics. However, the end result is likely to be the same. We need an alternative to treatment – in other words, a paradigm shift.” 

Improved biosecurity 

Prof Bragg says highly improved biosecurity is the only viable option for disease control in a post-antibiotic era. By using good biosecurity in poultry production, he says the mortality rates were reduced by 50%. 

Research has shown a direct link between the environmental microbial load in a hospital and HAIs; with a lower microbial load linked to lower incidence of HAIs including C. difficile infections (Boyce et al. 2008; Suleyman et al. 2018; Umemura et al., 2022). Therefore, the new paradigm is to reduce microbial contamination in the hospital environment to prevent HAIs. If there are fewer dangerous microorganisms in an environment, patient and staff exposure to these microorganisms will decrease, reducing the level of HAIs for staff and patients. However, to reduce the microbial loads in healthcare settings, effective cleaning and disinfection products need to be used. 

News Archive

UFS PhD student receives more than R5,8 million to take agricultural research to African farmers
2015-07-06

Prof Maryke Labuschagne and Bright Peprah. (Photo: Supplied)

Bright Peprah, a Plant Breeding PhD student from Ghana in the Department of Plant Sciences at the University of the Free State received an award from the competitive Program for Emerging Agricultural Research Leaders (PEARL) of the Bill and Melinda Gates Foundation (BMGF) for one of his projects.

From the more than 750 proposals for funding that were received from African researchers, only 19 received funding from PEARL. PEARL is an agricultural initiative by the BMGF to take agricultural research products to African farmers. It also aims at involving the youth and women in agriculture.

Peprah’s proposal to introgress beta carotene into farmer-preferred cassava landraces was part of the final 19 proposals funded. The project is being led by the Council for Scientific and Industrial Research (CSIR)Crops Research Institute (CRI), and has the International Institute of Tropical Agriculture (IITA) and the International Centre for Tropical Agriculture (CIAT) as international partners with Peprah as the principal investigator.


The development of nutrient-dense cassava cultivars needs attention to eliminate the ramifications of malnutrition among the poor in an inexpensive and more sustainable way.
Photo: Supplied

He received $473 000 (R5,8 million) for his project on the improvement of beta-carotene content in cassava.

Peprah decided on this project because the populations of underdeveloped and developing countries, such as Ghana, commonly suffer undernourishment and/or hidden hunger, predisposing them to diseases from micronutrients deficiencies. “Vitamin A deficiency constitutes an endemic public health problem which affects women and children largely,” he says.

“In Africa, cassava is widely consumed by the populace. Unfortunately, in these areas, malnutrition is endemic to a significant extent, partly due to the low micronutrients in this tuberous root crop, which is a major component of most household diets. It is for this reason that the development of nutrient- dense cassava cultivars needs much attention to eliminate the ramifications of malnutrition among the poor in an inexpensive and more sustainable way.

“To date we have selected top eight genotypes from germplasm collected from the International Institute of Tropical Agriculture (IITA) which are high in carotenoids and also poundable, a key trait to Ghanaian farmers. These eight genotypes have been planted at different locations in Ghana, and being evaluated by different stakeholders (consumers, researchers, producers, commercial farmers, processors, etc.). If found suitable, the genotypes will be released to farmers, which we hope will solve some of the micronutrient problems in Ghana.

“My projects seek to develop new cassava varieties that will have both high dry matter and beta carotene which has been reported to be negatively correlated (as one increase, the other decreases). The breeding method will be crossing varieties that are high in beta carotene with those with high dry matter, and checking the performance of the seedlings later. Developing such new varieties (yellow flesh cassava) will increase their adoption rate by Ghanaian farmers,” he said.

Prof Maryke Labuschagne, Professor in Plant Breeding in the Department Plant Sciences and Peprah’s study leader, said: “This project has the potential to alleviate vitamin A deficiency in the West African region, where this deficiency is rampant, causing blindness in many people, especially children."

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept